Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential Hypertension

Boehringer Ingelheim

Status: Completed

Conditions: Hypertension

Treatments: Drug: Telmisartan

Study type: Observational

Funder types: Industry

Identifiers

NCT02245464

502.479

Details and patient eligibility

About

The objective of this PMS study was to monitor and assess the safety of Micardis tablets in patients with hypertension over a period of 6 years

Enrollment: 13,066 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female patients diagnosed with essential hypertension
• Patients without prior experience with Micardis tablet

Exclusion criteria

• Known hypersensitivity to Micardis tablet
• Pregnancy or breastfeeding
• Biliary atresia
• Severe hepatic failure patients
• Severe renal failure patients

Trial design

13,066 participants in 1 patient group

Patients with essential hypertension

Treatment:

Drug: Telmisartan